Pooled annualized consumption of rFVIIa and aPCC in PwHAs with FVIII inhibitors across 24-week treatment intervals in the HAVEN 1, HAVEN 2, and HAVEN 4 studies
| Treatment for bleed . | Weeks 1-24 . | Weeks 25-48 . | Weeks 49-72 . | Weeks 73-96 . | Weeks 97-120 . | Weeks 121-44 . |
|---|---|---|---|---|---|---|
| Evaluable participants, n | 203 | 192 | 167 | 125 | 79 | 57 |
| rFVIIa AIR | 5.1 (1.7-11.9) | 1.2 (0.1-5.9) | 2.0 (0.3-7.3) | 2.3 (0.4-7.8) | 2.2 (0.3-7.6) | 1.4 (0.1-6.3) |
| rFVIIa consumption, μg/kg | 657.9 (608.5-710.1) | 114.3 (94.3-137.3) | 202.2 (175.3-232.1) | 147.3 (124.5-173.1) | 171.4 (146.7-199.1) | 93.5 (75.5-114.5) |
| aPCC AIR | 1.2 (0.1-6.0) | 0.5 (0-4.7) | 0.1 (0-3.9) | 0 (0-3.8) | 0 (0-3.8) | 0* |
| aPCC consumption, U/kg | 87.8 (70.4-108.2) | 11.6 (5.9-20.5) | 2.9 (0.6-8.7) | 0.5 (0-4.7) | 0.3 (0-4.3) | 0* |
| Treatment for bleed . | Weeks 1-24 . | Weeks 25-48 . | Weeks 49-72 . | Weeks 73-96 . | Weeks 97-120 . | Weeks 121-44 . |
|---|---|---|---|---|---|---|
| Evaluable participants, n | 203 | 192 | 167 | 125 | 79 | 57 |
| rFVIIa AIR | 5.1 (1.7-11.9) | 1.2 (0.1-5.9) | 2.0 (0.3-7.3) | 2.3 (0.4-7.8) | 2.2 (0.3-7.6) | 1.4 (0.1-6.3) |
| rFVIIa consumption, μg/kg | 657.9 (608.5-710.1) | 114.3 (94.3-137.3) | 202.2 (175.3-232.1) | 147.3 (124.5-173.1) | 171.4 (146.7-199.1) | 93.5 (75.5-114.5) |
| aPCC AIR | 1.2 (0.1-6.0) | 0.5 (0-4.7) | 0.1 (0-3.9) | 0 (0-3.8) | 0 (0-3.8) | 0* |
| aPCC consumption, U/kg | 87.8 (70.4-108.2) | 11.6 (5.9-20.5) | 2.9 (0.6-8.7) | 0.5 (0-4.7) | 0.3 (0-4.3) | 0* |
Unless otherwise noted, data are mean (95% CI).
95% CIs are not reported when all participants had a value of 0.